Hologic, Inc. — Cyborg Score 6/10

Solid
Medical Devices & Diagnostics - Women's Health Focus

Strategic Profile

Hologic has always thrived on innovations, with the FDA-approved 3DQuorum Imaging Technology representing the first of several products powered by the company's core AI platform, Genius AI. The company benefits from recurring revenue streams through service contracts for its installed base, though recent quarters have faced margin pressure with a 13.2% net profit margin compared with 18.4% in the prior year.

Cyborg Score Rationale

Hologic reported Q1 2026 revenue of $1.0 billion and basic EPS of $0.80, with trailing 12-month revenue of $4.1 billion. While the company maintains profitability and strong operational cash flow, slower forecast growth compared with the market, along with a 5-year earnings decline and a $346.8 million one-off loss, raise concerns about margin sustainability.

Top Insights

  • Pending Blackstone-TPG acquisition at ~$79/share represents ~46% premium; stockholder vote scheduled Feb 5, 2026 with expected H1 2026 close
  • Q1 2026 revenue growth modest at 2.5% YoY; organic surgical revenue growth only 3.2%, reflecting segment-specific challenges
  • Margin compression ongoing with net profit margin declining from 18.4% to 13.2% YoY; includes material one-off charges affecting profitability trends
  • Strong cash generation with operating cash flow up 21.4% to $229.9M in Q1 2026, offsetting profitability headwinds

Named Competitors

  • Mammography Systems — Medical imaging and diagnostics systems
  • Healthcare Equipment — Diagnostic imaging and life sciences solutions
  • Surgical Robotics — Minimally invasive surgical robotic systems
  • In Vitro Diagnostics — Molecular and genetic diagnostics platforms

Recent Developments

  • (January 2026) Launched Ultimate Defense cervical cancer awareness campaign with basketball player Erica Wheeler
  • (January 2026) Released Q1 FY2026 results with $1.05B revenue; non-GAAP EPS of $1.04
  • (May 2025) Entered definitive merger agreement with Blackstone and TPG at $76-79 per share valuation
  • (December 2025) Fiscal Q1 2026 operating cash flow increased 21.4% to $229.9 million

Open the full interactive Hologic, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →